Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib

被引：5
|
作者：
Ansai, Osamu [1 ]
Fujikawa, Hiroki [1 ]
Shimomura, Yutaka [1 ]
Abe, Riichiro [1 ]
机构：
[1] Niigata Univ, Grad Sch Sci & Technol, Div Dermatol, Chuo Ku, 1-757 Asahimachi dori, Niigata 9518510, Japan
来源：
JOURNAL OF DERMATOLOGY | 2017年 / 44卷 / 03期
关键词：
METASTATIC MELANOMA;
D O I：
10.1111/1346-8138.13534
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E15 / E16
页数：2
相关论文
共 50 条
  • [41] Use of Vemurafenib, a BRAF Inhibitor Along With Radiation Therapy in Melanoma Brain Metastasis
    Narayana, A.
    Mathew, M.
    Golfinos, J. G.
    Parker, E. C.
    Ott, P.
    Pavlick, A. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S302 - S303
  • [42] Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma
    Agemy, Steven A.
    Mehta, Ankur N.
    Pachydaki, Sophia I.
    Tewari, Asheesh
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2014, 24 (04) : 629 - 632
  • [43] Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
    Atzori, Maria Grazia
    Ceci, Claudia
    Ruffini, Federica
    Trapani, Mauro
    Barbaccia, Maria Luisa
    Tentori, Lucio
    D'Atri, Stefania
    Lacal, Pedro Miguel
    Graziani, Grazia
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (01) : 465 - 475
  • [44] Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
    Chik, Constance L.
    van Landeghem, Frank K. H.
    Easaw, Jacob C.
    Mehta, Vivek
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (05)
  • [45] BRAF-Inhibitor Vemurafenib verlängert progressionsfreies und Gesamtüberleben
    best practice onkologie, 2011, 6 (4) : 22 - 22
  • [46] High Incidence of Naevi-associated BRAF Wild-type Melanoma and Dysplastic Naevi under Treatment with the Class I BRAF Inhibitor Vemurafenib
    Goeppner, Daniela
    Mueller, Jan
    Krueger, Sabine
    Franke, Ingolf
    Gollnick, Harald
    Quist, Sven R.
    ACTA DERMATO-VENEREOLOGICA, 2014, 94 (05) : 517 - 520
  • [47] Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
    Subbiah, Vivek
    Sen, Shiraj
    Hess, Kenneth R.
    Janku, Filip
    Hong, David S.
    Khatua, Soumen
    Karp, Daniel D.
    Munoz, Javier
    Falchook, Gerald S.
    Groisberg, Roman
    Tsimberidou, Apostolia M.
    Sherman, Steven, I
    Hwu, Patrick
    Meric-Bernstam, Funda
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 12
  • [48] EVALUATION OF HO-1 INVOLVEMENT IN MELANOMA RESISTANCE TO BRAF INHIBITOR VEMURAFENIB
    Loi, Giulia
    Furfaro, AnnaLisa
    Pronzato, Maria Adelaide
    Pietra, Gabriella
    Nitti, Mariapaola
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 : A6 - A6
  • [49] Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma
    Sufficool, Kari E.
    Hepper, Donna M.
    Linette, Gerald P.
    Hurst, Eva A.
    Lu, Dongsi
    Lind, Anne C.
    Cornelius, Lynn A.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2014, 41 (07) : 568 - 575
  • [50] Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia
    Park, Jae H.
    Chung, Stephen S.
    Chung, Young Rock
    Won, Helen
    Teruya-Feldstein, Julie
    Berger, Michael
    Khawaja, Talal T.
    Lacouture, Mario E.
    Levine, Ross L.
    Abdel-Wahab, Omar
    Tallman, Martin S.
    BLOOD, 2013, 122 (21)
12345